Study record · Zenagamtide
Once-weekly subcutaneous zenagamtide in type 2 diabetes
HbA1c change ranged from -0.9% at 0.4 mg to -1.7% at 40 mg; all active groups showed significant improvement versus placebo.
Key result
HbA1c change ranged from -0.9% at 0.4 mg to -1.7% at 40 mg; all active groups showed significant improvement versus placebo.
Study details
Study designRandomized, double-blind, placebo-controlled dose-finding trial
PhasePhase II
PopulationAdults with type 2 diabetes on metformin with or without SGLT2 inhibitor
Sample size262
RouteSubcutaneous
Regimen / exposure0.4, 1.5, 5, 10, 20 or 40 mg once weekly after escalation from 0.2 mg
Duration36 weeks + 4-week follow-up
ComparatorPlacebo
Primary endpoint / questionChange in HbA1c
Safety resultMost adverse events were GI and mild-to-moderate; 21/261 exposed participants had serious adverse events, with no deaths.
Key limitationsPhase II, dose-ranging and diabetes-specific; longer-term outcomes remain investigational.
Registry / identifierPMID 42532080 / NCT06542874